Form 8-K
Material Company Update
2026-04-10
NTLA filed 8-K — material company event
Intellia Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Latest SEC filings for Intellia Therapeutics, Inc. (NTLA) explained in plain English: insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). Sourced directly from SEC EDGAR.
Intellia Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
LEONARD JOHN M (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
BASTA JAMES, listed as EVP, General Counsel at Intellia Therapeutics, Inc., reported an open-market sale of 1,211 NTLA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Lebwohl David (EVP, Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Dulac Edward J III (EVP, Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Schultes Birgit C (EVP, Chief Scientific Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Clark Eliana, listed as EVP, Chief Technical Officer at Intellia Therapeutics, Inc., reported an open-market sale of 607 NTLA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Dube Michael P (VP, Chief Accounting Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Intellia Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Intellia Therapeutics, Inc. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.
Intellia Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Intellia Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Intellia Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
LEONARD JOHN M, listed as Director, President and CEO at Intellia Therapeutics, Inc., reported an open-market sale of 34,146 NTLA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Schultes Birgit C, listed as EVP, Chief Scientific Officer at Intellia Therapeutics, Inc., reported an open-market sale of 8,508 NTLA shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.